MRC1 and cancer: Even if only in a minority of EOC cases are deficient in MMR [48,49], it is worth it to note that the Food and Drug Agency (FDA) granted anti-PD1 approval (Pembrolizumab) for MMR-deficient cancers regardless of histology.